Silo Pharma, Inc. SILO
are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that
address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company's lead program,
SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-based loaded implant
Last close
1.18
2026-10-23
Market cap
$1.9M
2026-06-30 share count
52-week range
1.10 - 10.43
Valuation FY2025 figures against the last close
P/S26.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.50
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $72.1K | $1.2K | $40.9K | $40.6K | — | — | — |
| Cost of revenue | $44.3K | $5.8K | $5.8K | $5.8K | $5.0K | $176.1K | $27.4K | — | — | — |
| Gross profit | $27.8K | $66.3K | $66.3K | $66.3K | $66.3K | -$135.2K | $13.2K | — | — | — |
| R&D | $2.2M | $2.4M | $845.1K | $1.3M | $693.9K | $26.2K | — | — | — | — |
| SG&A | — | — | $390.1K | $227.3K | $163.0K | $50.2K | $87.0K | $76.1K | $29.6K | — |
| Total operating expenses | $4.3M | $4.8M | $3.9M | $3.7M | $2.8M | $2.2M | $943.6K | $594.2K | $490.9K | — |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M | -$2.7M | -$2.2M | -$930.4K | -$594.2K | -$490.9K | — |
| Interest expense | $37.3K | $5.1K | $4.9K | $2.2K | $3.0K | $80 | $0 | — | — | — |
| Pre-tax income | -$4.2M | -$4.4M | -$3.6M | -$3.9M | $4.2M | -$2.7M | — | — | — | — |
| Income tax | — | — | — | — | $24.9K | — | — | — | — | — |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M | $3.9M | -$3.0M | -$1.0M | -$969.5K | $356.5K | — |
| EPS, basic | -0.50 | -1.19 | -1.20 | — | 0.04 | -0.05 | — | -0.02 | 0.01 | — |
| EPS, diluted | -0.50 | -1.19 | -1.20 | — | 0.04 | -0.05 | -0.04 | -0.02 | 0.01 | — |
| Shares, diluted (wtd. avg.) | 8.4M | 3.7M | 3.1M | 2.3M | 1.9M | 66.0M | — | 49.1M | 52.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.7M | $3.9M | $3.5M | $11.4M | $9.8M | $1.1M | $111.8K | $336.7K | $294.6K | $579.2K |
| Short-term investments | $2.1M | $3.2M | $4.1M | — | — | — | — | — | — | — |
| Receivables | — | — | — | $66.0K | — | $23.5K | — | — | — | — |
| Inventory | — | — | — | — | $58.4K | $33.5K | $156.4K | $27.0K | — | — |
| Total current assets | $7.4M | $7.1M | $7.7M | $11.6M | $10.4M | $1.4M | $493.8K | $626.0K | $1.6M | — |
| Other intangibles | $217.4K | $241.2K | — | — | — | — | — | $29.4K | — | — |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M | $1.4M | $493.8K | $855.4K | $1.6M | — |
| Accounts payable | $578.1K | $1.6M | $703.5K | $364.2K | $417.9K | $127.1K | $54.9K | $25.6K | $38.3K | — |
| Total current liabilities | $650.2K | $1.7M | $775.6K | $436.3K | $490.0K | $141.7K | $116.7K | $48.0K | $38.3K | — |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M | $146.0K | $116.7K | — | — | — |
| Retained earnings | -$19.5M | -$15.3M | -$10.9M | -$7.2M | -$3.3M | -$5.8M | -$2.7M | -$1.6M | — | — |
| Total equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M | $1.3M | -$22.9K | $407.4K | $1.2M | $846.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M | -$2.3M | -$1.2M | -$794.3K | $272.6K | -$284.6K | — |
| Stock-based compensation | $117.0K | $906.8K | $871.6K | $577.7K | $395.1K | $756.0K | $319.6K | $145.0K | $177.5K | — |
| Investing cash flow | $644.0K | $973.8K | -$4.1M | $86.7K | $7.2M | $39.0K | $186.7K | -$250.0K | — | — |
| Financing cash flow | $4.9M | $3.2M | -$471.1K | $4.9M | $3.8M | $2.1M | $382.7K | $19.5K | — | — |
| Buybacks | — | $173.1K | $1.0M | — | $1.0M | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-073367.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $40.6K | $40.9K | $1.2K | $72.1K | $72.1K | $72.1K | $72.1K |
| Gross profit | — | — | — | $13.2K | -$135.2K | $66.3K | $66.3K | $66.3K | $66.3K | $27.8K |
| Net income | — | $356.5K | -$969.5K | -$1.0M | -$3.0M | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed Item 5.03
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |